RESEARCH & PUBLICATIONS


Scott D Berkowitz

A publication record at a glance

183	31,078	67
ARTICLES	CITATIONS	h-INDEX

PUBLICATION ACTIVITY

Articles grouped into 3-year periods



MOST CITED IN THIS LIST

Rivaroxaban Versus Warfarin in Nonvalvular Atrial Fibrillation — 8,764
2011 New England Journal of Medicine

Oral Rivaroxaban for Symptomatic Venous Thromboembolism — 3,021
2010 New England Journal of Medicine

Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism — 2,230
2012 New England Journal of Medicine

This publication list was generated automatically from the exaly database without manual editing. It reflects the database records available when the document was created.

For the latest record and an updated publication list, visit the author profile:

https://exaly.com/author/6906787

Document version: 2026-11-23 (UTC) | Database snapshot: 2026-11-21

Ordered by citations, highest first

01	Rivaroxaban Versus Warfarin in Nonvalvular Atrial Fibrillation New England Journal of Medicine · 2011 · 365, 883-91 https://exaly.com/article/50109170	8,764 citations
02	Oral Rivaroxaban for Symptomatic Venous Thromboembolism New England Journal of Medicine · 2010 · 363, 2499-510 https://exaly.com/article/49675943	3,021 citations
03	Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism New England Journal of Medicine · 2012 · 366, 1287-97 https://exaly.com/article/52365597	2,230 citations
04	Rivaroxaban in Peripheral Artery Disease After Revascularization New England Journal of Medicine · 2020 · 382, 1994-2004 https://exaly.com/article/76998514	1,000 citations
05	Rivaroxaban for Stroke Prevention After Embolic Stroke of Undetermined Source New England Journal of Medicine · 2018 · 378, 2191-2201 https://exaly.com/article/71128136	969 citations
06	Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty (RECORD4): A Randomised Trial Lancet, The · 2009 · 373, 1673-1680 https://exaly.com/article/47091154	912 citations
07	Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism New England Journal of Medicine · 2017 · 376, 1211-1222 https://exaly.com/article/66684852	754 citations
08	Argatroban Anticoagulant Therapy in Patients With Heparin-Induced Thrombocytopenia Circulation · 2001 · 103, 1838-43 https://exaly.com/article/33374906	663 citations
09	Oral Rivaroxaban Versus Standard Therapy for the Treatment of Symptomatic Venous Thromboembolism: A Pooled Analysis of the EINSTEIN-DVT and PE Randomized Studies Thrombosis Journal · 2013 · 11, 1-10 https://exaly.com/article/55205441	506 citations
10	Rivaroxaban With or Without Aspirin in Patients With Stable Coronary Artery Disease: An International, Randomised, Double-Blind, Placebo-Controlled Trial Lancet, The · 2018 · 391, 205-218 https://exaly.com/article/69740770	489 citations

Ordered by citations, highest first

11	Higher Risk of Death and Stroke in Patients With Persistent vs. Paroxysmal Atrial Fibrillation: Results From the ROCKET-AF Trial European Heart Journal · 2015 · 36, 288-96 https://exaly.com/article/61216486	340 citations
12	Comparison of Ximelagatran With Warfarin for the Prevention of Venous Thromboembolism After Total Knee Replacement New England Journal of Medicine · 2003 · 349, 1703-12 https://exaly.com/article/35863550	325 citations
13	Rivaroxaban Compared With Standard Anticoagulants for the Treatment of Acute Venous Thromboembolism in Children: A Randomised, Controlled, Phase 3 Trial Lancet Haematology,the · 2020 · 7, e18-e27 https://exaly.com/article/75107430	307 citations
14	Ximelagatran vs Low-Molecular-Weight Heparin and Warfarin for the Treatment of Deep Vein Thrombosis: A Randomized Trial JAMA - Journal of the American Medical Association · 2005 · 293, 681-689 https://exaly.com/article/38869445	279 citations
15	Oral Rivaroxaban Versus Enoxaparin With Vitamin K Antagonist for the Treatment of Symptomatic Venous Thromboembolism in Patients With Cancer (EINSTEIN-DVT and EINSTEIN-PE): A Pooled Subgroup Analysis of Two Randomised Controlled Trials Lancet Haematology,the · 2014 · 1, e37-e46 https://exaly.com/article/59141529	261 citations
16	Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial JAMA - Journal of the American Medical Association · 2020 · 323, 130-139 https://exaly.com/article/77450411	259 citations
17	Rivaroxaban for the Prevention of Venous Thromboembolism After Hip or Knee Arthroplasty Thrombosis and Haemostasis · 2011 · 105, 444-453 https://exaly.com/article/50888441	254 citations
18	Factors Associated With Major Bleeding Events: Insights From the ROCKET AF Trial (Rivaroxaban Once-Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Journal of the American College of Cardiology · 2014 · 63, 891-900 https://exaly.com/article/59008000	223 citations

Ordered by citations, highest first

19	Allogeneic Blood Transfusions and Postoperative Infections After Total Hip or Knee Arthroplasty Journal of Bone and Joint Surgery - Series A · 2014 · 96, 272 https://exaly.com/article/59374307	219 citations
20	Intracranial Hemorrhage Among Patients With Atrial Fibrillation Anticoagulated With Warfarin or Rivaroxaban Stroke · 2014 · 45, 1304-12 https://exaly.com/article/58951739	215 citations
21	Incidence and Predictors of Bleeding After Contemporary Thrombolytic Therapy for Myocardial Infarction Circulation · 1997 · 95, 2508-16 https://exaly.com/article/86225559	208 citations
22	Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation: Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial JAMA Neurology · 2019 · 76, 764-773 https://exaly.com/article/73540543	201 citations
23	Acute Profound Thrombocytopenia After c7E3 Fab (Abciximab) Therapy Circulation · 1997 · 95, 809-13 https://exaly.com/article/86225687	196 citations
24	Ximelagatran Versus Warfarin for the Prevention of Venous Thromboembolism After Total Knee Arthroplasty Annals of Internal Medicine · 2002 · 137, 648-55 https://exaly.com/article/33880066	194 citations
25	Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation: Analysis From the ROCKET AF Trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Journal of the American College of Cardiology · 2013 · 61, 651-658 https://exaly.com/article/55120766	193 citations
26	Comparison of Three-Factor and Four-Factor Prothrombin Complex Concentrates Regarding Reversal of the Anticoagulant Effects of Rivaroxaban in Healthy Volunteers Journal of Thrombosis and Haemostasis · 2014 · 12, 1428-1436 https://exaly.com/article/58364299	188 citations
27	Cardiovascular Drug Development: Is It Dead or Just Hibernating? Journal of the American College of Cardiology · 2015 · 65, 1567-82 https://exaly.com/article/62191397	187 citations

Ordered by citations, highest first

28 Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial — 186 citations

Journal of the American College of Cardiology · 2015 · 66, 2271-2281

https://exaly.com/article/62747337

29 Complication Rates After Hip or Knee Arthroplasty in Morbidly Obese Patients — 184 citations

Clinical Orthopaedics and Related Research · 2013 · 471, 3358

https://exaly.com/article/54877536

30 Clinical Characteristics and Outcomes With Rivaroxaban vs. Warfarin in Patients With Non-Valvular Atrial Fibrillation but Underlying Native Mitral and Aortic Valve Disease Participating in the ROCKET AF Trial — 175 citations

European Heart Journal · 2014 · 35, 3377-85

https://exaly.com/article/57988098

31 Rivaroxaban or Aspirin for Patent Foramen Ovale and Embolic Stroke of Undetermined Source: A Prespecified Subgroup Analysis From the NAVIGATE ESUS Trial — 173 citations

Lancet Neurology, The · 2018 · 17, 1053-1060

https://exaly.com/article/70638875

32 Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation — 169 citations

Circulation · 2016 · 133, 352-60

https://exaly.com/article/65643182

33 Comparison of the Oral Direct Thrombin Inhibitor Ximelagatran With Enoxaparin as Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: A Phase 2 Dose-Finding Study — 161 citations

Archives of Internal Medicine · 2001 · 161, 2215-2221

https://exaly.com/article/33480684

34 Economic Assessment of Low-Molecular-Weight Heparin (Enoxaparin) Versus Unfractionated Heparin in Acute Coronary Syndrome Patients — 160 citations

Circulation · 1998 · 97, 1702-7

https://exaly.com/article/29510733

35 Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial — 158 citations

Stroke · 2014 · 45, 1739-47

https://exaly.com/article/59490393

36 Stroke Outcomes in the COMPASS Trial — 157 citations

Circulation · 2019 · 139, 1134-1145

https://exaly.com/article/72859152

Ordered by citations, highest first

37 Clinical Significance of Thrombocytopenia During a Non–ST-Elevation Acute Coronary Syndrome
156 citations
Circulation · 1999 · 99, 2892-900
https://exaly.com/article/30145684

38 Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF
155 citations
Journal of the American Heart Association · 2016 · 5, e002197
https://exaly.com/article/65626913

39 Management of Major Bleeding Events in Patients Treated With Rivaroxaban vs. Warfarin: Results From the ROCKET AF Trial
154 citations
European Heart Journal · 2014 · 35, 1873-80
https://exaly.com/article/58873240

40 Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease
152 citations
Circulation · 2020 · 141, 1841-1854
https://exaly.com/article/76999612

41 On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin
151 citations
Circulation · 2016 · 134, 37-47
https://exaly.com/article/65298214

42 Occurrence and Clinical Significance of Thrombocytopenia in a Population Undergoing High-Risk Percutaneous Coronary Revascularization
143 citations
Journal of the American College of Cardiology · 1998 · 32, 311-319
https://exaly.com/article/29283929

43 Comparison of Ximelagatran, an Oral Direct Thrombin Inhibitor, With Enoxaparin for the Prevention of Venous Thromboembolism Following Total Hip Replacement. A Randomized, Double-Blind Study
139 citations
Journal of Thrombosis and Haemostasis · 2003 · 1, 2119-2130
https://exaly.com/article/35235471

44 Digoxin Use in Patients With Atrial Fibrillation and Adverse Cardiovascular Outcomes: A Retrospective Analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)
139 citations
Lancet, The · 2015 · 385, 2363-2370
https://exaly.com/article/62285096

Ordered by citations, highest first

45 Embolic Strokes of Undetermined Source: Prevalence and Patient Features in the ESUS Global Registry
139 citations
International Journal of Stroke · 2016 · 11, 526-33
https://exaly.com/article/64066183

46 Efficacy and Safety of Rivaroxaban in Patients With Diabetes and Nonvalvular Atrial Fibrillation: The Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)
137 citations
American Heart Journal · 2015 · 170, 675-682.e8
https://exaly.com/article/61933182

47 Glycoprotein IIb/IIIa Integrin Blockade
121 citations
Circulation · 1998 · 98, 2629-35
https://exaly.com/article/29523392

48 Rationale and Design for the Vascular Outcomes Study of ASA Along With Rivaroxaban in Endovascular or Surgical Limb Revascularization for Peripheral Artery Disease (VOYAGER PAD)
119 citations
American Heart Journal · 2018 · 199, 83-91
https://exaly.com/article/69091124

49 Safety and Efficacy of Rivaroxaban in Pediatric Cerebral Venous Thrombosis (EINSTEIN-Jr CVT)
116 citations
Blood Advances · 2020 · 4, 6250-6258
https://exaly.com/article/86485913

50 Efficacy and Safety of Rivaroxaban vs. Warfarin in Patients With Non-Valvular Atrial Fibrillation and a History of Cancer: Observations From ROCKET AF
110 citations
European Heart Journal Quality of Care & Clinical Outcomes · 2019 · 5, 145-152
https://exaly.com/article/74488710

51 Efficacy and Safety of Rivaroxaban in Patients With Heart Failure and Nonvalvular Atrial Fibrillation
109 citations
Circulation: Heart Failure · 2013 · 6, 740-7
https://exaly.com/article/56371070

52 Evaluation of Drug-Induced Serious Hepatotoxicity (eDISH)
108 citations
Drug Safety · 2011 · 34, 243-252
https://exaly.com/article/50147456

53 Relationship Between Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results From the ROCKET AF Trial
106 citations
Journal of the American Heart Association · 2014 · 3, e000521
https://exaly.com/article/58560026

Ordered by citations, highest first

54 Efficacy and Safety of Low Molecular Weight Heparin (Ardeparin Sodium) Compared to Warfarin for the Prevention of Venous Thromboembolism After Total Knee Replacement Surgery: A Double-Blind, Dose-Ranging Study
102 citations
Thrombosis and Haemostasis · 1997 · 77, 032-038
https://exaly.com/article/84995495

55 Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization
101 citations
Circulation · 2020 · 142, 2219-2230
https://exaly.com/article/76562904

56 Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source
92 citations
Stroke · 2019 · 50, 3184-3190
https://exaly.com/article/72703279

57 Rivaroxaban for Secondary Stroke Prevention in Patients With Embolic Strokes of Undetermined Source: Design of the NAVIGATE ESUS Randomized Trial
90 citations
European Stroke Journal · 2016 · 1, 146-154
https://exaly.com/article/63536533

58 Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial
89 citations
JAMA Cardiology · 2021 · 6, 21-29
https://exaly.com/article/75551595

59 Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (From Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial)
87 citations
American Journal of Cardiology · 2017 · 119, 1989-1996
https://exaly.com/article/66539460

60 Rivaroxaban for Treatment of Pediatric Venous Thromboembolism. An Einstein-Jr Phase 3 Dose-Exposure-Response Evaluation
87 citations
Journal of Thrombosis and Haemostasis · 2020 · 18, 1672-1685
https://exaly.com/article/77562646

61 Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis
82 citations
Stroke · 2019 · 50, 2477-2485
https://exaly.com/article/71962240

Ordered by citations, highest first

62 Clinical Correlates and Course of Thrombocytopenia During Percutaneous Coronary Intervention in the Era of Abciximab Platelet Glycoprotein IIb/IIIa Blockade
80 citations
American Heart Journal · 2000 · 140, 74-80
https://exaly.com/article/32047694

63 Modifiable Risk Factors for Vascular Access Site Complications in the IMPACT II Trial of Angioplasty With Versus Without Eptifibatide
77 citations
Journal of the American College of Cardiology · 1998 · 31, 1518-1524
https://exaly.com/article/29283825

64 Is Thrombosis a Contributor to Heart Failure Pathophysiology? Possible Mechanisms, Therapeutic Opportunities, and Clinical Investigation Challenges
77 citations
International Journal of Cardiology · 2013 · 167, 1772-1782
https://exaly.com/article/55537566

65 Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial
74 citations
Stroke · 2020 · 51, 1797-1804
https://exaly.com/article/77649516

66 Rapid Assessment of Glycoprotein IIb/IIIa Blockade With the Platelet Function Analyzer (PFA-100) During Percutaneous Coronary Intervention
70 citations
American Heart Journal · 2001 · 141, 226-233
https://exaly.com/article/32390027

67 Novel Oral Anticoagulants and Reversal Agents: Considerations for Clinical Development
70 citations
American Heart Journal · 2015 · 169, 751-757
https://exaly.com/article/61244941

68 Use and Outcomes of Antiarrhythmic Therapy in Patients With Atrial Fibrillation Receiving Oral Anticoagulation: Results From the ROCKET AF Trial
65 citations
Heart Rhythm · 2014 · 11, 925-932
https://exaly.com/article/58712553

69 Oral Heparin Administration With a Novel Drug Delivery Agent (SNAC) in Healthy Volunteers and Patients Undergoing Elective Total Hip Arthroplasty
60 citations
Journal of Thrombosis and Haemostasis · 2003 · 1, 1914-1919
https://exaly.com/article/35235444

70 Blood Pressure Control and Stroke or Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: Results From the ROCKET AF Trial
60 citations
American Heart Journal · 2016 · 178, 74-84
https://exaly.com/article/65135163

Ordered by citations, highest first

71 Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source: Secondary Analysis of a Randomized Clinical Trial — 60 citations
JAMA Neurology · 2020 · 77, 1233-1240
https://exaly.com/article/75673590

72 Use of Concomitant Aspirin in Patients With Atrial Fibrillation: Findings From the ROCKET AF Trial — 57 citations
American Heart Journal · 2016 · 179, 77-86
https://exaly.com/article/65296417

73 Understanding Thrombocytopenia and Antigenicity With Glycoprotein IIb-IIIa Inhibitors — 56 citations
American Heart Journal · 1999 · 138, S317-S326
https://exaly.com/article/30725208

74 Rivaroxaban Versus Aspirin for Secondary Prevention of Ischaemic Stroke in Patients With Cancer: A Subgroup Analysis of the NAVIGATE ESUS Randomized Trial — 56 citations
European Journal of Neurology · 2020 · 27, 841-848
https://exaly.com/article/77285914

75 Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI) — 54 citations
Circulation · 2020 · 141, 1141-1151
https://exaly.com/article/76907055

76 Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease — 52 citations
Journal of the American College of Cardiology · 2021 · 78, 14-23
https://exaly.com/article/81426290

77 Safety and Efficacy of Anticoagulant Therapy in Pediatric Catheter-Related Venous Thrombosis (EINSTEIN-Jr CVC-VTE) — 51 citations
Blood Advances · 2020 · 4, 4632-4639
https://exaly.com/article/75468642

78 Oral Direct Thrombin Inhibitor Ximelagatran Compared With Warfarin for the Prevention of Venous Thromboembolism After Total Knee Arthroplasty — 50 citations
Journal of Bone and Joint Surgery - Series A · 2005 · 87, 2169-77
https://exaly.com/article/38707113

79 Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial — 50 citations
Journal of the American College of Cardiology · 2021 · 78, 317-326
https://exaly.com/article/81290089

Ordered by citations, highest first

80 Characterization of Patients With Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial
49 citations
Journal of Stroke and Cerebrovascular Diseases · 2018 · 27, 1673-1682
https://exaly.com/article/69430868

81 Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial
48 citations
Circulation · 2021 · 144, 1104-1116
https://exaly.com/article/81610671

82 Clinical Outcomes With Rivaroxaban in Patients Transitioned From Vitamin K Antagonist Therapy
47 citations
Annals of Internal Medicine · 2013 · 158, 861-8
https://exaly.com/article/57072911

83 Efficacy of Abciximab Readministration in Coronary Intervention
45 citations
American Journal of Cardiology · 2000 · 85, 435-440
https://exaly.com/article/31519653

84 Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (From the ROCKET AF Trial)
44 citations
American Journal of Cardiology · 2017 · 120, 588-594
https://exaly.com/article/66508667

85 Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis
44 citations
Circulation · 2019 · 140, 1451-1459
https://exaly.com/article/72679777

86 Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD
44 citations
Circulation · 2021 · 144, 1831-1841
https://exaly.com/article/91106477

87 The Effects of Rivaroxaban on the Complications of Surgery After Total Hip or Knee Replacement: Results From the RECORD Programme
43 citations
Bone and Joint Journal · 2012 · 94-B, 1573-1578
https://exaly.com/article/53285687

88 End of Study Transition From Study Drug to Open-Label Vitamin K Antagonist Therapy
43 citations
Circulation: Cardiovascular Quality and Outcomes · 2013 · 6, 470-8
https://exaly.com/article/56484715

Ordered by citations, highest first

89 Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin — 42 citations
Journal of the American College of Cardiology · 2019 · 74, 1519-1528
https://exaly.com/article/72736656

90 Is There a Role for Pharmacokinetic/Pharmacodynamic-Guided Dosing for Novel Oral Anticoagulants? — 40 citations
American Heart Journal · 2018 · 199, 59-67
https://exaly.com/article/69584579

91 Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial — 40 citations
Journal of the American Heart Association · 2018 · 7, e008755
https://exaly.com/article/70989193

92 Rivaroxaban Versus Standard Anticoagulation for Acute Venous Thromboembolism in Childhood. Design of the EINSTEIN-Jr Phase III Study — 39 citations
Thrombosis Journal · 2018 · 16, 1-11
https://exaly.com/article/70486073

93 Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Randomized Clinical Trial — 39 citations
JAMA Neurology · 2021 · 78, 11-20
https://exaly.com/article/77822492

94 Hemodilution With Other Blood Reinfusion Techniques in Total Hip Arthroplasty — 38 citations
Clinical Orthopaedics and Related Research · 1997 · 339, 132
https://exaly.com/article/28054359

95 Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications — 38 citations
Clinical and Applied Thrombosis/Hemostasis · 2016 · 22, 412-22
https://exaly.com/article/65580591

96 Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin — 38 citations
Circulation · 2017 · 135, 1001-1003
https://exaly.com/article/66139131

97 Low-Dose Rivaroxaban and Aspirin Among Patients With Peripheral Artery Disease: A Meta-Analysis of the COMPASS and VOYAGER Trials — 38 citations
European Journal of Preventive Cardiology · 2022 · 29, e181-e189
https://exaly.com/article/81980854

Ordered by citations, highest first

98 New Heparin Dosing Recommendations for Patients With Acute Coronary Syndromes — 37 citations
American Journal of Medicine · 2001 · 110, 641-650
https://exaly.com/article/32372916

99 Incidence of Neuraxial Haematoma After Total Hip or Knee Surgery: RECORD Programme (Rivaroxaban vs. Enoxaparin) — 35 citations
Acta Anaesthesiologica Scandinavica · 2013 · 57, 565-572
https://exaly.com/article/55932631

100 Native Valve Disease in Patients With Non-Valvular Atrial Fibrillation on Warfarin or Rivaroxaban — 35 citations
Heart · 2016 · 102, 1036-1043
https://exaly.com/article/65574482

101 Estimating Individual Lifetime Benefit and Bleeding Risk of Adding Rivaroxaban to Aspirin for Patients With Stable Cardiovascular Disease: Results From the COMPASS Trial — 35 citations
European Heart Journal · 2019 · 40, 3771-3778a
https://exaly.com/article/72667031

102 Determination of Platelet Aggregation Inhibition During Percutaneous Coronary Intervention With the Platelet Function Analyzer PFA-100 — 34 citations
American Heart Journal · 2002 · 144, 151-158
https://exaly.com/article/34245158

103 Atrial Cardiopathy and Nonstenosing Large Artery Plaque in Patients With Embolic Stroke of Undetermined Source — 33 citations
Stroke · 2020 · 51, 938-943
https://exaly.com/article/75190660

104 Risk Factors and Clinical Outcomes in Chronic Coronary and Peripheral Artery Disease: An Analysis of the Randomized, Double-Blind COMPASS Trial — 32 citations
European Journal of Preventive Cardiology · 2020 · 27, 296-307
https://exaly.com/article/75008842

105 Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization: Insights From VOYAGER PAD — 32 citations
Journal of the American College of Cardiology · 2021 · 78, 1768-1778
https://exaly.com/article/91258754

Ordered by citations, highest first

106 The Determinants of Activated Partial Thromboplastin Time, Relation of Activated Partial Thromboplastin Time to Clinical Outcomes, and Optimal Dosing Regimens for Heparin Treated Patients With Acute Coronary Syndromes: A Review of GUSTO-IIb

Journal of Thrombosis and Thrombolysis · 2002 · 14, 91-101

https://exaly.com/article/34840920

31 citations

107 Benefit–Risk Assessment of Rivaroxaban Versus Enoxaparin for the Prevention of Venous Thromboembolism After Total Hip or Knee Arthroplasty

Vascular Health and Risk Management · 2014 · 10, 157-167

https://exaly.com/article/57388506

31 citations

108 Hospitalizations in Patients With Atrial Fibrillation: An Analysis From ROCKET AF

Europace · 2016 · 18, 1135-42

https://exaly.com/article/64165786

31 citations

109 Prospective Comparison of Hemorrhagic Complications After Treatment With Enoxaparin Versus Unfractionated Heparin for Unstable Angina Pectoris or Non–ST-Segment Elevation Acute Myocardial Infarction

American Journal of Cardiology · 2001 · 88, 1230-1234

https://exaly.com/article/33221009

30 citations

110 Predictors of Recurrent Ischemic Stroke in Patients With Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial

Journal of Stroke and Cerebrovascular Diseases · 2019 · 28, 2273-2279

https://exaly.com/article/73075873

30 citations

111 Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline

Stroke · 2020 · 51, 2901-2909

https://exaly.com/article/76146361

29 citations

112 The Discovery and Development of Rivaroxaban

Annals of the New York Academy of Sciences · 2011 · 1222, 64-75

https://exaly.com/article/51039647

28 citations

113 Heparin Dosing and Outcome in Acute Coronary Syndromes: The GUSTO-IIb Experience

American Heart Journal · 2002 · 144, 73-80

https://exaly.com/article/34245120

26 citations

114 Comparison of Two Aspirin Doses on Ischemic Stroke in Post-Myocardial Infarction Patients in the Warfarin (Coumadin) Aspirin Reinfarction Study (CARS)

American Journal of Cardiology · 2001 · 88, 541-546

https://exaly.com/article/33220709

25 citations

Ordered by citations, highest first

115 Branch Atheromatous Disease Diagnosed as Embolic Stroke of Undetermined Source: A Sub-Analysis of NAVIGATE ESUS
25 citations
International Journal of Stroke · 2019 · 14, 915-922
https://exaly.com/article/73049518

116 High-Sensitivity Cardiac Troponin T for Risk Stratification in Patients With Embolic Stroke of Undetermined Source
25 citations
Stroke · 2020 · 51, 2386-2394
https://exaly.com/article/77168630

117 Bleeding Complications With Platelet Glycoprotein IIb/IIIa Receptor Antagonists
25 citations
Current Opinion in Hematology · 1999 · 6, 334
https://exaly.com/article/85549217

118 Rivaroxaban: A Novel Oral Anticoagulant for the Prevention and Treatment of Several Thrombosis-Mediated Conditions
24 citations
Annals of the New York Academy of Sciences · 2013 · 1291, 42-55
https://exaly.com/article/55880347

119 Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial
24 citations
JACC: Cardiovascular Interventions · 2016 · 9, 1694-1702
https://exaly.com/article/64506249

120 Efficacy and Safety of Rivaroxaban Plus Aspirin in Women and Men With Chronic Coronary or Peripheral Artery Disease
24 citations
Cardiovascular Research · 2021 · 117, 942-949
https://exaly.com/article/77690124

121 Oral Direct Thrombin Inhibitor Ximelagatran Compared With Warfarin for the Prevention of Venous Thromboembolism After Total Knee Arthroplasty
24 citations
Journal of Bone and Joint Surgery - Series A · 2005 · 87, 2169
https://exaly.com/article/87926762

122 Relation Between Inhibition of Platelet Aggregation and Clinical Outcomes
23 citations
American Heart Journal · 1998 · 136, s43-s50
https://exaly.com/article/29289553

123 Low-Dose Rivaroxaban Plus Aspirin in Older Patients With Peripheral Artery Disease Undergoing Acute Limb Revascularization: Insights From the VOYAGER PAD Trial
23 citations
European Heart Journal · 2021 · 42, 4040-4048
https://exaly.com/article/81913301

Ordered by citations, highest first

124 Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PAD
22 citations
Circulation · 2023 · 148, 1919-1928
https://exaly.com/article/170708362

125 Rivaroxaban in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Bypass Surgery With Venous and Prosthetic Conduits
21 citations
Journal of Vascular Surgery · 2023 · 77, 1107-1118.e2
https://exaly.com/article/158093616

126 Antithrombotic Therapy in Peripheral Artery Disease: Current Evidence and Future Directions
21 citations
Journal of Cardiovascular Development and Disease · 2023 · 10, 164
https://exaly.com/article/162289999

127 Intracranial and Systemic Atherosclerosis in the NAVIGATE ESUS Trial: Recurrent Stroke Risk and Response to Antithrombotic Therapy
20 citations
Journal of Stroke and Cerebrovascular Diseases · 2020 · 29, 104936
https://exaly.com/article/75579978

128 Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization
19 citations
JAMA Network Open · 2022 · 5, e2215580-e2215580
https://exaly.com/article/148547442

129 The Discovery of Rivaroxaban: Translating Preclinical Assessments Into Clinical Practice
18 citations
Frontiers in Pharmacology · 2013 · 4, 66677
https://exaly.com/article/57216437

130 Clinical Presentation and Therapeutic Management of Venous Thrombosis in Young Children: A Retrospective Analysis
18 citations
Thrombosis Journal · 2018 · 16, 1-9
https://exaly.com/article/70369244

131 Coagulation Complicating Cardiopulmonary Bypass in a Patient With Heparin-Induced Thrombocytopenia Receiving the Heparinoid, Danaparoid Sodium
17 citations
Journal of Cardiothoracic and Vascular Anesthesia · 1997 · 11, 875-877
https://exaly.com/article/28293216

132 Associations Between Model-Predicted Rivaroxaban Exposure and Patient Characteristics and Efficacy and Safety Outcomes in Patients With Non-Valvular Atrial Fibrillation
17 citations
Journal of Thrombosis and Thrombolysis · 2020 · 50, 20-29
https://exaly.com/article/77572279

Ordered by citations, highest first

133 Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial — 17 citations

Journal of the American College of Cardiology · 2021 · 77, 511-525

https://exaly.com/article/77873182

134 Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS Trial — 16 citations

Stroke · 2022 · 53, 45-52

https://exaly.com/article/82112365

135 Rivaroxaban Versus Aspirin for Prevention of Covert Brain Infarcts in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS MRI Substudy — 16 citations

International Journal of Stroke · 2022 · 17, 799-805

https://exaly.com/article/123120864

136 Sex-Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD — 16 citations

Journal of the American Heart Association · 2022 · 11, e024655

https://exaly.com/article/148463649

137 Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients From Mainland China With Nonvalvular Atrial Fibrillation: A Subgroup Analysis From the ROCKET AF Trial — 15 citations

Thrombosis Research · 2017 · 156, 184-190

https://exaly.com/article/66319028

138 Prevention of Arterial and Venous Thrombotic Events in Symptomatic Peripheral Arterial Disease Patients After Lower Extremity Revascularization in the VOYAGER PAD Trial: Dual Anticoagulant/Antiplatelet Regimen vs Antiplatelet Therapy Alone — 15 citations

Journal of Thrombosis and Haemostasis · 2022 · 20, 1193-1205

https://exaly.com/article/134587097

139 Low-Dose Rivaroxaban Plus Aspirin in Patients With Peripheral Artery Disease Undergoing Lower Extremity Revascularization With and Without Concomitant Coronary Artery Disease: Insights From VOYAGER PAD — 15 citations

Circulation · 2024 · 149, 1536-1539

https://exaly.com/article/185200992

140 Progress in Point-of-Care Laboratory Testing for Assessing Platelet Function — 14 citations

American Heart Journal · 1998 · 136, s51-s65

https://exaly.com/article/29289552

141 Net Clinical Benefit of Rivaroxaban Compared With Warfarin in Atrial Fibrillation: Results From ROCKET AF — 14 citations

International Journal of Cardiology · 2018 · 257, 78-83

https://exaly.com/article/68779762

Ordered by citations, highest first

142 Associations Between Model-Predicted Rivaroxaban Exposure and Patient Characteristics and Efficacy and Safety Outcomes in the Treatment of Venous Thromboembolism

14 citations

Journal of Thrombosis and Thrombolysis · 2020 · 50, 1-11

https://exaly.com/article/77572278

143 Antithrombotic Therapy After Prosthetic Cardiac Valve Implantation: Potential Novel Antithrombotic Therapies

13 citations

American Heart Journal · 2001 · 142, 7-13

https://exaly.com/article/32390179

144 Rationale, Design, and Baseline Participant Characteristics in the MRI and Cognitive Substudy of the Cardiovascular Outcomes for People Using Anticoagulation Strategies Trial

13 citations

International Journal of Stroke · 2019 · 14, 270-281

https://exaly.com/article/71811729

145 Current Knowledge of the Platelet Glycoprotein IIb/IIIa Receptor Antagonists for the Treatment of Coronary Artery Disease

12 citations

Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research · 2000 · 30, 27-43

https://exaly.com/article/31088183

146 Antithrombotic Outcome Trials in Acute Coronary Syndromes: Seeking the Optimal Balance Between Safety and Efficacy

12 citations

European Heart Journal · 2013 · 34, 1621-9

https://exaly.com/article/55160576

147 Clinical Factors Associated With Peripheral Artery Disease in Patients With Documented Coronary Artery Disease: A Post Hoc Analysis of the COMPASS Trial

12 citations

Atherosclerosis · 2021 · 331, 38-44

https://exaly.com/article/81627808

148 Low-Dose Rivaroxaban Plus Aspirin in Fragile Patients After Lower Extremity Revascularization

12 citations

Journal of the American College of Cardiology · 2024 · 84, 801-811

https://exaly.com/article/188497804

149 Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (From Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)

11 citations

American Journal of Cardiology · 2017 · 120, 1837-1840

https://exaly.com/article/67354659

Ordered by citations, highest first

150 Efficacy and Safety of Rivaroxaban Compared With Warfarin in Patients With Carotid Artery Disease and Nonvalvular Atrial Fibrillation: Insights From the ROCKET AF Trial
11 citations
Clinical Cardiology · 2018 · 41, 39-45
https://exaly.com/article/69060043

151 Cardiovascular Consequences of Discontinuing Low-Dose Rivaroxaban in People With Chronic Coronary or Peripheral Artery Disease
11 citations
Heart · 2021 · 107, 1130-1137
https://exaly.com/article/80535942

152 Rivaroxaban in Patients With Recent Peripheral Artery Revascularization and Renal Impairment: The VOYAGER PAD Trial
11 citations
Journal of the American College of Cardiology · 2021 · 78, 757-759
https://exaly.com/article/81868365

153 Once-Daily Oral Rivaroxaban Compared With Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis After Total Knee Replacement: RECORD4
11 citations
Blood · 2008 · 112, 35-35
https://exaly.com/article/86465067

154 Quantitative Benefit–Risk Assessment of Rivaroxaban for the Prevention of Venous Thromboembolism
11 citations
Blood · 2009 · 114, 169-169
https://exaly.com/article/86465845

155 Efficacy and Safety of Rivaroxaban Versus Placebo After Lower Extremity Bypass Surgery: A Post Hoc Analysis of a “CASPAR Like” Outcome From VOYAGER PAD
11 citations
Clinical Cardiology · 2022 · 45, 1143-1146
https://exaly.com/article/155717933

156 Quantitative Benefit–Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial
11 citations
Journal of the American Heart Association · 2024 · 13, e032782
https://exaly.com/article/177853142

157 Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial
9 citations
Journal of the American Heart Association · 2017
https://exaly.com/article/66365313

158 Associations Between Model-Predicted Rivaroxaban Exposure and Patient Characteristics and Efficacy and Safety Outcomes in the Prevention of Venous Thromboembolism
9 citations
Journal of Thrombosis and Thrombolysis · 2020 · 50, 12-19
https://exaly.com/article/77572280

Ordered by citations, highest first

159 Improvement in Walking Impairment Following Surgical and Endovascular Revascularization: Insights From VOYAGER PAD
9 citations
Vascular Medicine · 2022 · 27, 343-349
https://exaly.com/article/144849454

160 Impact of Polyvascular Disease on Patients With Atrial Fibrillation: Insights From ROCKET AF
8 citations
American Heart Journal · 2018 · 200, 102-109
https://exaly.com/article/68834741

161 Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling
8 citations
CPT: Pharmacometrics and Systems Pharmacology · 2019 · 8, 805-814
https://exaly.com/article/72247348

162 Risk Stratification of Cardiovascular Complications Using CHA2DS2-VASc and CHADS2 Scores in Chronic Atherosclerotic Cardiovascular Disease
8 citations
International Journal of Cardiology · 2021 · 337, 9-15
https://exaly.com/article/81832034

163 Influence of Model-Predicted Rivaroxaban Exposure and Patient Characteristics on Efficacy and Safety Outcomes in Patients With Acute Coronary Syndrome
7 citations
Therapeutic Advances in Cardiovascular Disease · 2019 · 13, 1753944719863641
https://exaly.com/article/71988795

164 Frequency and Predictors of Major Bleeding in Patients With Embolic Strokes of Undetermined Source
7 citations
Stroke · 2020 · 51, 2139-2147
https://exaly.com/article/76879440

165 Treatment of Established Deep Vein Thrombosis: A Review of the Therapeutic Armamentarium
7 citations
Orthopedics · 1995 · 18, 18-20
https://exaly.com/article/89371301

166 Assessment of Days Alive Out of Hospital as a Possible End Point in Trials of Stroke Prevention for Atrial Fibrillation: A ROCKET AF Analysis
5 citations
Journal of the American Heart Association · 2024 · 13, e028951
https://exaly.com/article/185466473

167 Rivaroxaban Versus Warfarin in Patients With Atrial Fibrillation Enrolled in Latin America: Insights From ROCKET AF
4 citations
American Heart Journal · 2021 · 236, 4-12
https://exaly.com/article/80791586

Ordered by citations, highest first

168 Long-Term Antithrombotic Therapy in Patients With Chronic Coronary Syndrome: An Updated Review of Current Evidence
4 citations
Clinical Therapeutics · 2025 · 47, 511-518
https://exaly.com/article/200067819

169 Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings From ROCKET AF
3 citations
Cardiology and Therapy · 2019 · 8, 283-295
https://exaly.com/article/72003915

170 Regional, Sex, and Age Differences in Diagnostic Testing Among Participants in the NAVIGATE-ESUS Trial
2 citations
International Journal of Stroke · 2021 · 16, 55-62
https://exaly.com/article/78045553

171 Unplanned Index Limb Revascularization With Rivaroxaban Versus Placebo in Patients With Critical Limb-Threatening Ischemia After Endovascular and Surgical Treatment: Insights From VOYAGER PAD
2 citations
Circulation · 2024 · 149, 635-637
https://exaly.com/article/176494319

172 Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD
2 citations
Journal of the American Heart Association · 2025 · 14, e039752
https://exaly.com/article/205940403

173 Response by Piccini et Al to Letters Regarding Article, “Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation”
1 citations
Circulation · 2016 · 134, e7-8
https://exaly.com/article/63779256

174 Pharmacotherapy for Diabetes and Stroke Risk: Results From ROCKET AF
1 citations
Heart Rhythm O2 · 2021 · 2, 215-222
https://exaly.com/article/80963940

175 Low-Dose Rivaroxaban Plus Aspirin in Patients With PAD Undergoing Lower Extremity Revascularization With and Without History of Prior Limb Revascularization: Insight From the VOYAGER-PAD Trial
1 citations
Circulation: Cardiovascular Interventions · 2026 · 19, e015229
https://exaly.com/article/210919972

Ordered by citations, highest first

176 Development of New Antithrombotic Drugs for Children (Part 1): Guidance From the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis and the Pedi-ATLAS Group

1 citations

Journal of Thrombosis and Haemostasis · 2026 · 24, 3360-3368

https://exaly.com/article/212609174

177 Introduction

0 citations

American Heart Journal · 2001 · 141, 847-848

https://exaly.com/article/32390122

178 Comment on Model-Based Meta-Analysis to Evaluate Optimal Doses of Direct Oral Factor Xa Inhibitors in Atrial Fibrillation Patients

0 citations

Blood Advances · 2018 · 2, 3193-3195

https://exaly.com/article/71016745

179 Termination Based on Event Accrual in per Protocol Versus Intention to Treat in the ROCKET AF Trial

0 citations

Journal of the American Heart Association · 2021 · 10, e022485

https://exaly.com/article/82399687

180 Accuracy in the Measurement of Compartment Pressures: A Comparison of Three Commonly Used Devices

0 citations

Journal of Bone and Joint Surgery - Series A · 2006 · 88, 1165

https://exaly.com/article/94514545

181 Methods, Design, and Initial Results of an Angiographic Core Lab From VOYAGER-PAD

0 citations

Vascular Medicine · 2024 · 29, 143-152

https://exaly.com/article/177154083

182 Early Risk of Major Adverse Limb Events Following Lower Extremity Revascularization in the VOYAGER-PAD Trial

0 citations

JACC: Cardiovascular Interventions · 2025 · 18, 1211-1213

https://exaly.com/article/198981707

183 Prescription of Aspirin Plus Low-Dose Rivaroxaban in Patients With Peripheral Artery Disease After Lower-Extremity Revascularization

0 citations

Vascular Medicine · 2025 · 30, 318-320

https://exaly.com/article/200503474

End of list · 183 articles. Citation counts use Exaly's peer-reviewed cohort.